Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical pharmacology of the angiotensin receptor antagonists.

Literature DB >> 11416682

Clinical pharmacology of the angiotensin receptor antagonists.

D A Sica¹.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2001 PMID： 11416682 PMCID： PMC8099280 DOI： 10.1111/j.1524-6175.2001.00832.x

Source DB: PubMed Journal: J Clin Hypertens (Greenwich) ISSN： 1524-6175 Impact factor: 3.738

× No keyword cloud information.

35 in total

Review 1. Practical considerations of the pharmacology of angiotensin receptor blockers.

Authors: M M McConnaughey; J S McConnaughey; A J Ingenito
Journal: J Clin Pharmacol Date: 1999-06 Impact factor: 3.126

2. Pharmacokinetics of intravenous and oral losartan in patients with heart failure.

Authors: M W Lo; J Toh; S E Emmert; M A Ritter; C I Furtek; H Lu; W S Colucci; B F Uretsky; E Rucinska
Journal: J Clin Pharmacol Date: 1998-06 Impact factor: 3.126

3. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor.

Authors: M Ojima; Y Inada; Y Shibouta; T Wada; T Sanada; K Kubo; K Nishikawa
Journal: Eur J Pharmacol Date: 1997-01-14 Impact factor: 4.432

Review 4. Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations.

Authors: M B Bottorff; D M Tenero
Journal: Pharmacotherapy Date: 1999-04 Impact factor: 4.705

5. Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist.

Authors: D M Colussi; C Parisot; M L Rossolino; L A Brunner; G Y Lefèvre
Journal: J Clin Pharmacol Date: 1997-03 Impact factor: 3.126

6. Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers.

Authors: N N Vachharajani; W C Shyu; T J Chando; D W Everett; D S Greene; R H Barbhaiya
Journal: J Clin Pharmacol Date: 1998-08 Impact factor: 3.126

7. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans.

Authors: M W Lo; M R Goldberg; J B McCrea; H Lu; C I Furtek; T D Bjornsson
Journal: Clin Pharmacol Ther Date: 1995-12 Impact factor: 6.875

Review 8. Kinetics of angiotensin-converting enzyme inhibitors in renal failure.

Authors: D A Sica
Journal: J Cardiovasc Pharmacol Date: 1992 Impact factor: 3.105

9. Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174.

Authors: D D Christ
Journal: J Clin Pharmacol Date: 1995-05 Impact factor: 3.126

10. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators.

Authors: S Oparil; R Guthrie; A J Lewin; T Marbury; K Reilly; J Triscari; J A Witcher
Journal: Clin Ther Date: 1998 May-Jun Impact factor: 3.393

3 in total